Le journal des biotechs : Entretien avec Thomas Lienard, DG de Bone Therapeutics et Christophe Dombu, analyste chez Portzamparc (French)
Find out more soon about our expertise as an innovative company and our objective of addressing important unmet medical needs in the areas of innate immunity, inflammation and organ/function repair.